Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Myositis and metastatic melanoma

Nazia Karsan, Robert Barker and Damian Wren
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.15-2-210
Clin Med April 2015
Nazia Karsan
ADepartment of Neurology, Frimley Park Hospital NHS Foundation Trust, Camberley, UK;
Roles: SpR neurology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: naziakarsan@hotmail.com
Robert Barker
BDepartment of Radiology, Frimley Park Hospital NHS Foundation Trust, Camberley, UK;
Roles: consultant radiologist,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damian Wren
CDepartment of Neurology, Frimley Park Hospital NHS Foundation Trust, Camberley, UK
Roles: consultant neurologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

A 70-year-old man with known metastatic melanoma presented with a widespread rash and feeling generally unwell, two weeks after starting treatment with vemurafenib (a BRAF inhibitor). The symptoms improved after discontinuing the treatment but he went on to develop a Bell's palsy after it was recommenced. Following completed recovery, the medication was restarted for a third time.

Four to six weeks later the patient developed a proximal myopathy and an elevated creatine kinase of 30,000 IU/l. In addition, he had myoglobulinuria, renal impairment and jaundice with deranged liver function tests. He was diagnosed with rhabdomyolysis. Cessation of therapy on this occasion led to clinical recovery and normalisation of the biochemical features. He had a normal blood muscle antibody screen and electromyography confirmed proximal limb myopathic changes. A muscle biopsy was not undertaken as it was felt that this myositis was most likely due to the effects of vemurafenib. On stopping the drug his clinical features and biochemical abnormalities resolved.

Vemurafenib is a biological BRAF inhibitor specifically targeted against the serine–threonine kinase enzyme. It is licensed for use in BRAF mutation-positive or metastatic melanoma.1 To the best of our knowledge, the muscle effects observed in this patient have not been previously reported for this class of medications. This patient experienced some of known adverse effects of this agent early in the course of treatment, such as VII palsy.2 In one phase III study of vemurafenib, 38% of patients required dose changes because of side effects.3

At presentation, a whole body MRI was performed (Fig 1). Melanoma metastases were seen in the left humeral head (long white arrow) and spleen (short white arrow). There was symmetrical proximal active myositis with oedematous high signal in several muscle groups (long green arrows) compared with normal muscle signal (green arrowhead).

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Whole body magnetic resonance imaging (MRI).

  • © 2015 Royal College of Physicians

References

  1. 1 .↵
    1. McArthur GA
    , Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15:323–32.
    OpenUrlCrossRefPubMed
  2. 2 .↵
    1. Datapharm
    . Zelboraf 240 mg Film-coated Tablets. Available online at www.medicines.org.uk/emc/medicine/26056 [Accessed 5 February].
  3. 3 .↵
    1. Chapman PB
    , Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364;2507–16.
    OpenUrlCrossRefPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Myositis and metastatic melanoma
Nazia Karsan, Robert Barker, Damian Wren
Clinical Medicine Apr 2015, 15 (2) 210; DOI: 10.7861/clinmedicine.15-2-210

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Myositis and metastatic melanoma
Nazia Karsan, Robert Barker, Damian Wren
Clinical Medicine Apr 2015, 15 (2) 210; DOI: 10.7861/clinmedicine.15-2-210
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Images of the month 1: Ischaemic stroke due to pulmonary arteriovenous fistula
  • Images of the month 1: Histoacryl glue embolisation to the right ventricle following treatment for gastric varices
  • Images of the month 2: Disseminated nocardiosis in a 60-year-old woman with sarcoidosis
Show more Image of the month

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians